[1]冯云洁,孙 烁,徐雨坷,等.国家医保谈判药品在三级医院和定点零售药店的可及性分析[J].卫生经济研究,2025,42(06):24-27,31.
　FENG Yunjie,SUN Shuo,XU Yuke,et al.Assessment of the Availability and Accessibility of National Negotiated Drugs in Tertiary Hospitals and Designated Retail Pharmacies[J].Journal Press of Health Economics Research,2025,42(06):24-27,31.
点击复制

国家医保谈判药品在三级医院和定点零售药店的可及性分析

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
42
期数:
2025年06期
页码:
24-27,31
栏目:
药械管理
出版日期:
2025-05-29

文章信息/Info

Title:
Assessment of the Availability and Accessibility of National Negotiated Drugs in Tertiary Hospitals and Designated Retail Pharmacies
作者:
冯云洁1; 孙 烁1; 徐雨坷1; 史艺威1; 张骅晨1; 汤少梁1
1.南京中医药大学卫生经济管理学院，江苏 南京 210023
Author(s):
FENG Yunjie;  SUN Shuo;  XU Yuke;  SHI Yiwei;  ZHANG Huachen;  TANG Shaoliang
School of Health Economics and Management, Nanjing University of Chinese Medicine, Nanjing Jiangsu 210023, China
关键词:
国家医保谈判药品; 三级医院; 定点零售药店; 药品可及性
Keywords:
national negotiated drugs;  tertiary hospitals;  designated retail pharmacies;  drug accessibility
分类号:
R95
文献标志码:
A
摘要:
目的：分析2023年版国家医保目录新增谈判药品在医疗机构和定点零售药店的配备情况，评估“双通道”政策实施效果。方法：选取105种新增的国家谈判药品作为样本，分析在各地三级医院、定点零售药店的配备率。结果：26个省区市的国家谈判药品在三级医院的配备率超过50%，但三级医院的平均药品配备率较低，慢性病药品的三级医院和定点零售药店覆盖率高于肿瘤和罕见病药品。结论：国家谈判药品在三级医院和定点零售药店的可及性有待提高，应优化新药进院路径，打破处方壁垒，关注地区差异，创新“互联网+双通道”模式，全面保障药品可及性。
Abstract:
Objective To analyze the availability and accessibility of newly negotiated drugs in the 2023 version of the National Health Insurance Catalogue in medical institutions and designated retail pharmacies, and to assess the implementation effect of the "dual-channel" policy. Methods 105 new negotiated medicines were selected as samples to analyze the provision rate in tertiary hospitals and designated retail pharmacies in different regions. Results In 26 provinces, autonomous regions, and municipalities, the provision rate of national negotiated drugs in tertiary hospitals exceeded 50%, but the average drug provision rate in tertiary hospitals was lower, and the level of coverage rate of chronic disease drugs in tertiary hospitals and designated retail pharmacies was higher than oncology drugs and rare disease drugs. Conclusion The accessibility of national negotiated drugs in tertiary hospitals and designated retail pharmacies needs to be improved. It is necessary to optimize the pathway for new drugs to enter hospitals, break down the prescription barriers, pay attention to regional differences, and innovate the "Internet + dual-channel" model, so as to comprehensively guarantee the accessibility of drugs.

参考文献/References:

[1] 国务院办公厅关于完善公立医院药品集中采购工作的指导意见 [EB/OL]. （2015-02-28）[2024-11-21].https://www.gov.cn/zhengce/content/2015-02/28/content_9502.htm.
[2] 国家医保局，国家卫生健康委. 关于建立完善国家医保谈判药品“双通道”管理机制的指导意见[EB/OL]. （2021-04-22）[2024-11-21].https://www.gov.cn/zhengce/zhengceku/2021-05/10/content_5605595.htm.
[3] Gong S,Wang Y,Pan X,et al.The availability and affordability of orphan drugs for rare diseases in China[J].Orphanet J Rare Dis, 2016(11):20.
[4] Mendis S,Fukino K,Cameron A,et al.The availability and affordability of selected essential medicines for chronic diseases in six low-and middle-income countries[J].Bull World Health Organ, 2007,85(04):279-88.
[5] 国务院办公厅.国务院关于实施健康中国行动的意见[EB/OL]. （2019-07-15）[2024-11-25].https://www.gov.cn/zhengce/content/2019-07/15/content_5409492.htm.
[6] 卫生健康委.健康中国行动（2019—2030年）[EB/OL].（2019-07-09）[2024-11-25].https://www.gov.cn/xinwen/2019-07/15/content_ 5409694.htm.
[7] 上海市医疗保障局，上海市卫生健康委员会.关于重申加快推动创新药械临床应用有关事项的通知 [EB/OL]. （2023-12-29）[2024-11-24].https://ybj.sh.gov.cn/qtwj/20231229/f6aa919f11114782b2dc 92ed4167e6d7.html.
[8] 国家医疗保障局，国家卫生健康委.关于适应国家医保谈判常态化持续做好谈判药品落地工作的通知 [EB/OL].（2021-09-09） [2024-11-23].https://www.gov.cn/zhengce/zhengceku/2021-09/11/ content_5636762.htm.
[9] 陈非非，张璐莹，俞纯璐，等.DRG付费下创新医疗技术的额外支付机制研究——基于国际经验与启示[J].卫生经济研究，2023，40（08）：28-32.
[10] 孙向彦，曲薪池.药占比管制下过度医疗行为多阶段动态演化研究[J].中国管理科学，2024，32（08）：308-321.
[11] 高超，宣七一，周城城，等.公立医院价格改革对门急诊次均费用的影响——以绍兴市为例[J].中国医疗保险，2024（05）：67-72.
[12] 国家卫生健康委办公厅关于建立全国罕见病诊疗协作网的通知 [EB/OL]. （2019-02-12）[2024-11-23].https://www.gov.cn/zhengce/ zhengceku/2019-10/08/content_5436962.htm.
[13] 李鑫，张素雅，马文兵，等.罕见病药品可及性的伦理考量与策略探索[J].医学与哲学，2024，45（18）：19-23.
[14] 莫曼君，吴志强，黄宁，等. “双通道”管理机制下电子处方流转与医保线上结算分析[J].中国医院管理，2024，44（06）：73-76，86.
[15] 付瑞枫，茅宁莹. “双通道”背景下国谈创新药零售终端流通现状[J].卫生经济研究，2023，40（02）：24-27，33.

相似文献/References:

[1]黄 河,胡琳琳,刘 智,等.三级医院改善医疗服务：第二轮评估结果与讨论[J].卫生经济研究,2018,(04):10.
[2]方金鸣,刘 玲,彭义香,等.CHS-DRG支付改革对医院运行的影响分析[J].卫生经济研究,2022,39(5):67.
　FANG Jin-ming,LIU Ling,PENG Yi-xiang,et al.Analysis of the Impact of CHS-DRG Payment Reform on Hospital Operation[J].Journal Press of Health Economics Research,2022,39(06):67.
[3]于文超,孙华君,陈 营,等.天津市三级医院医疗护理员队伍建设及管理实践研究[J].卫生经济研究,2023,40(1):65.
　YU Wenchao,SUN Huajun,CHEN Ying,et al.A Study on the Construction and Management of Medical Nursing Staff Team in Tertiary Hospitals in Tianjin[J].Journal Press of Health Economics Research,2023,40(06):65.

更新日期/Last Update: 2025-05-29